Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

28/07/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 1.03%, closing at 52747.32 points; the Nasdaq Composite dropped by 0.22%, closing at 24876.91 points; the S&P 500 Index rose by 0.21%, closing at 7428.78 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Enigmatig Limited Class A: Overnight gain 85.8%, Surges Amid Technical Rebound, Cross-Border Compliance Demand, and Low-Liquidity Dynamics

Enigmatig Limited Class A Enigmatig Limited (the "Company") was incorporated in the Cayman Islands on May 30, 2023, with its principal headquarters established in Singapore. The Company operates as an international consulting firm specializing in the cross-border financial services sector. The Company is dedicated to providing clients with comprehensive, one-stop cross-border financial licensing solutions alongside a full suite of ancillary support services. Through its operating subsidiaries, Enigmatig Limited conducts business operations across key financial hubs, including Singapore, Hong Kong SAR, and Mainland China, positioning itself as an integrated service provider within the cross-border financial advisory landscape.

Enigmatig Limited Class A (EGG) Surges 85.8% Amid Confluence of Catalysts Shares of Enigmatig Limited Class A (EGG) recorded a remarkable single-day gain of 85.8%, driven by a convergence of multiple factors. First, the stock had accumulated a year-to-date decline of approximately 27.4%, leaving it technically oversold and primed for a mean-reversion rebound. Second, the company's core business — providing cross-border financial licensing services across Singapore, Hong Kong, and mainland China — has garnered heightened market attention amid rising demand for cross-border regulatory compliance solutions. Third, founded in May 2023, Enigmatig Limited Class A (EGG) carries a relatively limited market capitalization and constrained liquidity as a newly listed small-cap issuer. This low-float characteristic significantly amplifies price elasticity upon concentrated capital inflows, contributing to the pronounced intraday spike observed in today's trading session.

OPKO Health, Inc.: Overnight gain 33.1%, Surges Driven by Earnings Beat, Raised Guidance, and Key Partnership Progress

OPKO Health, Inc. – Corporate Profile & Key Pharmaceutical Portfolio Incorporated in the State of Delaware in October 1991, OPKO Health, Inc. is a diversified healthcare enterprise strategically positioned to establish industry-leading capabilities across high-growth segments of the global healthcare market. The Company's pharmaceutical operations are anchored by two core product assets. The first is Rayaldee (calcifediol), an FDA-approved extended-release formulation indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 to 4 chronic kidney disease (CKD) and vitamin D insufficiency. The second is Somatrogon, a once-weekly human growth hormone injection currently under development and commercialization in partnership with Pfizer Inc., one of the world's leading biopharmaceutical companies. The collaboration with Pfizer underscores OPKO Health's commitment to advancing innovative therapeutic solutions through strategic alliances with global industry leaders. Together, these flagship assets reflect the Company's focused efforts to address significant unmet medical needs while driving long-term shareholder value through a differentiated and diversified healthcare platform.

OPKO Health, Inc. (OPK) Surges 33.1% on Triple Catalysts Shares of OPKO Health, Inc. (OPK) rallied sharply, driven by a confluence of multiple positive catalysts. First, the company reported Q2 EPS of $(0.01), significantly beating consensus estimates of $(0.08), while revenue reached $163.5 million, surpassing market expectations by approximately 24.59%. Pharmaceutical segment revenue surged roughly 60% year-over-year to $89 million, including $33.6 million in royalties and milestone payments. Second, management raised fiscal year 2026 revenue guidance to $560–$585 million, exceeding the Street consensus of $536.88 million. Third, partner Entera Bio successfully completed an oversubscribed $275 million private placement, which will advance the Phase 1 clinical development of EB612 in collaboration with OPKO Health, Inc. (OPK) for hypoparathyroidism. The convergence of these three catalysts propelled OPK shares up 33.1% in a single session, lifting year-to-date gains to 30.9%.

The Top 10 Daily Gainers in the USA market are listed as follows: